A young woman whose dystrophic epidermolysis bullosa (DEB) pruriginosa was caused by a newly identified gene mutation responded well…
Articles by Margarida Maia, PhD
Abeona Therapeutics is seeking U.S. Food and Drug Administration (FDA) approval for EB-101, an investigational cell therapy for…
The just-approved gene therapy Vyjuvek (beremagene geperpavec) soon will be available to people with dystrophic epidermolysis bullosa (DEB)…
A young boy in Spain was evaluated for developmental delay and found to have three different genetic diseases: junctional…
Researchers in the U.K. used a gene editing tool to fix a common mutation causing recessive dystrophic epidermolysis bullosa…
New study findings point to neutrophils, a type of immune cells, as possible players in epidermolysis bullosa acquisita (EBA)…
The level of soluble transferrin receptor (sTfR) in blood may help diagnose more children with anemia, a condition caused by…
Disease activity may remain stable over years in people with epidermolysis bullosa, but will increase in the absence of…
An adenine base editor (ABE), a kind of molecular tool, was used to fix a disease-causing mutation in lab-grown fibroblasts…
Getting gene editing based on CRISPR, a kind of molecular scissors, delivered directly into cells may help restore the production…
Many patients with dystrophic epidermolysis bullosa (DEB) need the help of a caregiver at home, and this adds up…
Three small children with junctional epidermolysis bullosa (JEB) developed extensive damage to the airways and lungs, which led to…